FDA vaccine advisor says decision to boost Covid-19 has been expedited by Biden administration’s Sept.
Three reports have been published Wednesday support the argument that people may need a booster dose of Pfizer’s Covid-19 vaccine over time, and they suggest that such boosters would be safe.
The reports are part of a set of statements that will be discussed Friday by the US Food and Drug Administration’s vaccine advisors. The U.S. Food and Drug Administration is considering a request from Pfizer to approve a third booster dose of its vaccine for most people six months after they receive their first two doses of the vaccine.
But while the FDA clearly indicated that it would grant emergency use authorization for the Pfizer and Moderna vaccines last December, that it would grant the EUA to the Johnson & Johnson vaccine in February and that it would fully approve the Pfizer vaccine last month, it was remarkably neutral on the question. Anabolic doses for the general public.
There are “several potentially relevant studies, but the FDA has not independently reviewed or verified the baseline data or their conclusions,” she said in a statement. A briefing document released on Wednesday Prior to the meeting of the Advisory Committee on Vaccines and Related Biological Products.
One of the reports is Official data presentation From Israel released earlier this month which showed booster doses of the vaccine not only raised immunity as measured in the blood, but also showed a real reduction in infection.
Two others, sponsored by Pfizer, support the argument that immunity, as measured in blood, begins to wane over time after people get the first two doses. Someone shows a booster that restores that immunity.
The reports, all published in the New England Journal of Medicine, are used by Pfizer and some federal officials to support the argument that most people will need booster doses beginning about six months after they are initially vaccinated.
Read more Here.